Biotechnology · Waltham, Massachusetts, United States
$24.27
+2.19% (+$0.52)2026-07-09
Smart-Money SignalDistribution · 27/100— Insiders are net sellers over 90 days (-$80.2M, 94 sales vs 6 buys)
Net Income-$120.9M
EPS$-0.73
Market Cap$4.0B
Price Performance
Historical data including institutional events
Company Profile
J
John Cox
CEO & Executive Director
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
